Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of diabetes and its complications
- Publicado em
- 4 nov 2025
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function
Shigehiro Katayama, Stefan D Anker, Dalong Zhu, SungGyun Kim, Ming-Ju Wu, Daiji Kawanami, Peter Rossing, Luis Miguel Ruilope, Christiane Ahlers, Meike Brinker et al.
Descritores MeSH
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Naphthyridines
- Mineralocorticoid Receptor Antagonists
- Kidney
- Renal Insufficiency, Chronic
- Humans
- Male
- Middle Aged
- Treatment Outcome
Veja também
Estudos relacionados
- Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
- Renal effects and safety between Asian and non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists
- Finerenone in Type 1 Diabetes and Chronic Kidney Disease